MGMT and melanoma: It is worth noting that the epigenetic silencing of MGMT has been associated with a significantly improved response to DTIC/TMZ single-agent therapy, a longer progression-free survival (PFS) in stage IV melanoma patients [83], and prolonged survival in stage III melanoma patients locoregionally treated with melphalan [84].